PARIS (Reuters) – France, Italy and Belgium acted to stop making use of hydroxychloroquine to treat patients struggling with COVID-19, the illness triggered by the new coronavirus, in the middle of concerns about the safety of the generic anti-malaria drug.
SUBMIT IMAGE: A nurse reveals a pill of hydroxychloroquine, amid the coronavirus illness (COVID-19) outbreak, at Nossa Senhora da Conceicao hospital in Porto Alegre, Brazil, April 23,2020 REUTERS/Diego Vara
France on Wednesday cancelled a decree permitting medical facility doctors to give the medication, while the Italian Medication Agency (AIFA) suspended authorization to utilize hydroxychloroquine for COVID-19 outside clinical trials.
Belgium’s medicine agency warned versus utilizing the drug to treat the infection any more except within continuous scientific registered trials. It stated trials aiming to assess the drug should also take prospective dangers into factor to consider.
The sudden changes highlight the challenge fo